Orchid Pharma touches the roof on getting EIR report from USFDA for Alathur facility

21 Sep 2017 Evaluate

Orchid Pharma is currently trading at its upper circuit limit of Rs. 21.45, up by 3.55 points or 19.83% from its previous closing of Rs. 17.90 on the BSE.

The scrip opened at Rs. 18.20 and has touched a high and low of Rs. 21.45 and Rs. 17.80 respectively. So far 349654 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 45.85 on 28-Sep-2016 and a 52 week low of Rs. 16.70 on 15-Sep-2017.

Last one week high and low of the scrip stood at Rs. 21.45 and Rs. 16.70 respectively. The current market cap of the company is Rs. 160.58 crore.

The promoters holding in the company stood at 26.68%, while institutions and non-institutions held 5.05% and 68.27% respectively.

Orchid Pharma has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility located at SIDCO Industrial Estate, Alathur, Kanchipuram District, Tamil Nadu, India. This facility was inspected by US FDA in May 2017.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

824.35 -11.10 (-1.33%)
11-Dec-2025 11:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.00
Dr. Reddys Lab 1269.00
Cipla 1501.55
Zydus Lifesciences 921.00
Lupin 2072.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×